GlassScriptPhysician profile
Cyd G Williams
NPI 1285613232
$2,824.72
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $301 · 2021: $265 · 2022: $481 · 2023: $484 · 2024: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,229.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $520.33 | 2019-2023 | Lo Loestrin Fe |
| Hologic Sales and Service, LLC | $368.29 | 2020-2024 | Acessa Provu System, Aptima |
| Astellas Pharma US INC | $361.52 | 2023-2024 | Veozah, Myrbetriq |
| Radius Health, INC. | $290.58 | 2019-2024 | Tymlos |
| Aspira Women'S Health INC | $106.70 | 2022-2024 | Ova1 |
| Channel Medsystems, INC. | $95.30 | 2022 | |
| Therapeuticsmd, INC. | $93.04 | 2020-2022 | |
| Mayne Pharma Commercial LLC | $80.38 | 2022-2024 | |
| Agile Therapeutics, INC. | $78.76 | 2021-2024 | Twirla |
| Bayer Healthcare Pharmaceuticals INC. | $69.96 | 2019-2024 | |
| Exeltis, USA INC. | $64.08 | 2019-2023 | Slynd |
| Avion Pharmaceuticals | $61.60 | 2021-2022 | |
| Duchesnay USA Incorporated | $59.74 | 2019 | |
| Amgen INC. | $58.45 | 2019-2024 | Prolia, Evenity |
| Evofem Biosciences, INC. | $54.63 | 2021-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $53.07 | 2023-2024 | Nexplanon |
| Coopersurgical, INC. | $48.39 | 2020-2024 | Paragard T 380a |
| Mylan Pharmaceuticals INC. | $43.91 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $42.06 | 2019-2024 | Gardasil 9, Gardasil |
| Medela LLC | $38.81 | 2019 | |
| Pfizer INC. | $35.23 | 2022-2024 | |
| Biogen, INC. | $29.94 | 2024 | |
| Daiichi Sankyo INC. | $28.95 | 2019 | |
| Glaxosmithkline, LLC. | $28.76 | 2019-2020 | |
| Scynexis, INC. | $26.53 | 2022 | |
| Allergan, INC. | $26.38 | 2019 | |
| Vertical Pharmaceuticals, LLC | $17.20 | 2019 | |
| Millicent US INC | $15.30 | 2019 | |
| Lilly USA, LLC | $14.24 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cyd Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.